Biotech Stocks Buzz

August 13, 2015

The $3.83B company on August 6, 2015 announced the publication of new data from its ongoing open-label safety extension study, the -015 Study, with NUPLAZID™ in patients with Parkinson’s disease psychosis (PDP) in the July 31 online issue of the Journal of the American Medical Directors Association. This is the first published report evaluating the long-term impact of antipsychotics on mortality and serious adverse events in patients with PDP.